A prismatic view of the epigenetic-metabolic regulatory axis in breast cancer therapy resistance
Open Access
- 8 May 2024
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 43 (23) , 1727-1741
Abstract
Epigenetic regulation established during development to maintain patterns of transcriptional expression and silencing for metabolism and other fundamental cell processes can be reprogrammed in cancer, providing a molecular mechanism for persistent alterations in phenotype. Metabolic deregulation and reprogramming are thus an emerging hallmark of cancer with opportunities for molecular classification as a critical preliminary step for precision therapeutic intervention. Yet, acquisition of therapy resistance against most conventional treatment regimens coupled with tumor relapse, continue to pose unsolved problems for precision healthcare, as exemplified in breast cancer where existing data informs both cancer genotype and phenotype. Furthermore, epigenetic reprograming of the metabolic milieu of cancer cells is among the most crucial determinants of therapeutic resistance and cancer relapse. Importantly, subtype-specific epigenetic-metabolic interplay profoundly affects malignant transformation, resistance to chemotherapy, and response to targeted therapies. In this review, we therefore prismatically dissect interconnected epigenetic and metabolic regulatory pathways and then integrate them into an observable cancer metabolism-therapy-resistance axis that may inform clinical intervention. Optimally coupling genome-wide analysis with an understanding of metabolic elements, epigenetic reprogramming, and their integration by metabolic profiling may decode missing molecular mechanisms at the level of individual tumors. The proposed approach of linking metabolic biochemistry back to genotype, epigenetics, and phenotype for specific tumors and their microenvironment may thus enable successful mechanistic targeting of epigenetic modifiers and oncometabolites despite tumor metabolic heterogeneity.Keywords
Funding Information
- Biochemistry
- Cell Biology
This publication has 209 references indexed in Scilit:
- BRCA1 Affects Lipid Synthesis through Its Interaction with Acetyl-CoA CarboxylaseJournal of Biological Chemistry, 2006
- Glutathione in Cancer Biology and TherapyCritical Reviews in Clinical Laboratory Sciences, 2006
- Why do cancers have high aerobic glycolysis?Nature Reviews Cancer, 2004
- Inhibition of fatty acid synthase (FAS) suppressesHER2/neu(erbB-2) oncogene overexpression in cancer cellsProceedings of the National Academy of Sciences, 2004
- Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis.2003
- Glutamine and its relationship with intracellular redox status, oxidative stress and cell proliferation/deathThe International Journal of Biochemistry & Cell Biology, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Continuous Fatty Acid Oxidation and Reduced Fat Storage in Mice Lacking Acetyl-CoA Carboxylase 2Science, 2001
- Methylation of the BRCA1 gene in sporadic breast cancer.1997
- Metabolism of breast cancer cells as revealed by non-invasive magnetic resonance spectroscopy studiesBreast Cancer Research and Treatment, 1994